Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
QuintilesIMS
Harvard Business School
Novartis
Deloitte
Cipla
UBS
McKesson
Covington
Mallinckrodt

Generated: August 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018851

« Back to Dashboard
NDA 018851 describes INDOMETHACIN, which is a drug marketed by Sun Pharm Inds, Glenmark Pharms Ltd, Sun Pharm Inds Inc, Zydus Pharms Usa Inc, Jubilant Generics, Parke Davis, Hetero Labs Ltd Iii, Inwood Labs, Cycle Pharms Ltd, Pioneer Pharms, Able, G And W Labs, Ivax Sub Teva Pharms, Mylan, Duramed Pharms Barr, Chartwell Rx, Chartwell Molecules, Watson Labs, Halsey, Fresenius Kabi Usa, Mylan Pharms Inc, Teva, Aurobindo Pharma Ltd, Pliva, Amneal Pharms, Heritage Pharms Inc, Novast Labs Ltd, Sandoz, Mutual Pharm, Watson Labs Inc, Avanthi Inc, Glenmark Generics, Superpharm, West-ward Pharms Int, and Hospira Inc, and is included in fifty-nine NDAs. It is available from fifty-two suppliers. Additional details are available on the INDOMETHACIN profile page.

The generic ingredient in INDOMETHACIN is indomethacin sodium. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indomethacin sodium profile page.

Summary for NDA: 018851

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 018851

Suppliers and Packaging for NDA: 018851

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
INDOMETHACIN
indomethacin
CAPSULE;ORAL 018851 NDA Heritage Pharmaceuticals Inc. 23155-010 23155-010-01 100 CAPSULE in 1 BOTTLE, PLASTIC (23155-010-01)
INDOMETHACIN
indomethacin
CAPSULE;ORAL 018851 NDA Heritage Pharmaceuticals Inc. 23155-010 23155-010-10 1000 CAPSULE in 1 BOTTLE, PLASTIC (23155-010-10)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength25MG
Approval Date:May 18, 1984TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength50MG
Approval Date:May 18, 1984TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Citi
Deloitte
Federal Trade Commission
US Department of Justice
Fuji
Baxter
McKesson
Medtronic
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot